New Insights into Gene Research and Therapy for Diabetes Mellitus
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: 15 January 2026 | Viewed by 21
Special Issue Editors
Interests: type 1 diabetes; gene therapy; molecular biology of endocrine diseases
Special Issue Information
Dear Colleagues,
Diabetes mellitus, or diabetes, is a group of related metabolic diseases characterized by high blood sugar levels. Type 1 diabetes (T1D) is caused by the autoimmune destruction of the insulin-producing beta (b)-cells of the pancreas, resulting in hyperglycaemia and life-threatening complications such as retinopathy, neuropathy, cardiac issues, and diseases of the central nervous system. Type 2 diabetes is a chronic disorder associated with insulin resistance and sedentary lifestyle practices. Gene therapy offers a promising avenue for treating/curing T1D, in particular by preventing b-cell destruction and engineering insulin-secreting cells through the expression of b-beta cell transcription factors.
This Special Issue seeks reviews, original journal articles, and opinions examining new insights outlining the various gene research and gene transfer methods, including viral gene therapy techniques used to date and promising novel techniques for the maintenance of euglycemia in the treatment of diabetes. Specifically, although gene therapy is not widely examined for T2D, insights into the expression of genes in the pancreas that improve insulin production or the modification of genes that regulate glucose metabolism are highly relevant.
Prof. Dr. Ann Simpson
Dr. Najah Therese Nassif
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gene therapy
- type 1 diabetes
- type 2 diabetes
- glycemic control
- beta-cell transcription factors
- insulin granules
- viral vectors
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
